<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00984620</url>
  </required_header>
  <id_info>
    <org_study_id>1220.40</org_study_id>
    <secondary_id>2009-012579-90</secondary_id>
    <nct_id>NCT00984620</nct_id>
  </id_info>
  <brief_title>Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)</brief_title>
  <official_title>Antiviral Effect and Safety of Once Daily BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-naive Patients for 12 or 24 Weeks as Combination Therapy With Pegylated Interferon-alpha 2a and Ribavirin (Randomised, Open Label, Phase II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To compare the antiviral efficacy and safety of a 12-week with a 24-week treatment of BI
      201335 at a dose of 120 mg once daily, with a 24-week background of pegylated
      interferon-alpha 2a (PegIFN) plus ribavirin (RBV), in treatment-naïve patients infected with
      hepatitis C virus (HCV) genotype 1
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virological Response at Week 28 (W28VR)</measure>
    <time_frame>28 weeks</time_frame>
    <description>Virological response at Week 28: The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at Week 28.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rapid Virological Response at Week 4 (RVR)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Rapid virological response at week 4 (RVR): The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at week 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological Response at Week 24 (W24VR)</measure>
    <time_frame>24 weeks</time_frame>
    <description>virological response at week 24 (W24VR): The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological Response at Week 36 (W36VR)</measure>
    <time_frame>36 weeks</time_frame>
    <description>Virological response at week 36 (W36VR): the patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at week 36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of Treatment Response (ETR)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>End of Treatment Response (ETR): The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at end of all therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained Virological Response (SVR24) at 24 Weeks After Completion of All Therapy</measure>
    <time_frame>72 weeks</time_frame>
    <description>Sustained Virological Response (SVR24) at 24 weeks: The patients who reached plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at 24 weeks after completion of all Hepatitis C virus (HCV) therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Load (HCV RNA) at All Visits During Treatment and Follow-up</measure>
    <time_frame>From baseline to 72 weeks</time_frame>
    <description>Viral load of Hepatitis C virus Ribonucleic acid (HCV RNA) at all visits during treatment (TRT) and follow-up, ie. change from baseline viral load at all visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach a Plasma HCV RNA Level BLD While on Treatment</measure>
    <time_frame>48 weeks</time_frame>
    <description>Time to reach a plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) level below the lower limit of detection (BLD) while on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Abnormalities and Study Medication Tolerabilities</measure>
    <time_frame>48 weeks</time_frame>
    <description>Participants with possible clinically significant laboratory test abnormalities observed in functional groups: Haematology, Coagulation, Electrolytes, Enzymes, Substrates and Differentials, automatic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinically Relevant Abnormalities Vital Signs, and Physical Examination</measure>
    <time_frame>48 weeks</time_frame>
    <description>No number of participants with clinically relevant abnormalities in vital signs and physical examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (1)</measure>
    <time_frame>baseline and 48 weeks</time_frame>
    <description>Change from baseline (CFB) in Red blood cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (2)</measure>
    <time_frame>baseline and 48 weeks</time_frame>
    <description>Change from baseline (CFB) in haematocrit and Eosinophils.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (3)</measure>
    <time_frame>baseline and 48 weeks</time_frame>
    <description>Change from baseline (CFB) in Platelets and white blood cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (4)</measure>
    <time_frame>baseline and 48 weeks</time_frame>
    <description>Change from baseline (CFB) in Sodium, Bicarbonate, Cholesterol total, Triglyceride, and Glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (5)</measure>
    <time_frame>baseline and 48 weeks</time_frame>
    <description>Change from baseline (CFB) in AST/GOT, ALT/GPT, Alka. phosphatase, GGT, Creatine kinase, Lipase, and Amylase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (6)</measure>
    <time_frame>baseline and 48 weeks</time_frame>
    <description>Change from baseline (CFB) in PT-INR (ratio).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>short arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients to receive BI201335 with PegIFN/RBV for 12 wks followed by 12 weeks PegIFN/RBV with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>long arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients to receive BI201335 with PegIFN/RBV for 24 wks with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of BI 201335 NA 3 days after first administration of PegIFN/RBV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>BI 201335</description>
    <arm_group_label>long arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 201335</intervention_name>
    <description>BI 201335</description>
    <arm_group_label>short arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon-alpha (IFN)</intervention_name>
    <description>Pegylated Interferon-alpha</description>
    <arm_group_label>short arm</arm_group_label>
    <arm_group_label>long arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Ribavirin (RBV)</description>
    <arm_group_label>short arm</arm_group_label>
    <arm_group_label>long arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Chronic hepatitis C infection of genotype 1

          2. Therapy-naïve to interferon, pegylated interferon, and ribavirin

          3. HCV viral load &gt; 100.000 IU/ml at screening

          4. Liver biopsy or fibroscan within two years prior to screening that provides evidence
             of any degree of fibrosis or cirrhosis

          5. Normal retinal finding on fundoscopy within 6 months prior to Day 1

          6. Age 18 to 70 years

        Exclusion criteria:

          1. HCV of mixed genotype (1/2, 1/3, and 1/4) .

          2. Patients who have been previously treated with at least one dose of any protease
             inhibitor

          3. Evidence of liver disease due to causes other than chronic HCV infection

          4. Positive for HIV-1 or HIV-2 antibodies

          5. Hepatitis B virus (HBV) infection

          6. Decompensated liver disease, or history of decompensated liver disease

          7. Active malignancy or history of malignancy within the last 5 years

          8. History of alcohol or drug abuse (except cannabis) within the past 12 months.

          9. Body Mass Index &lt; 18 or &gt; 35 kg/m2.

         10. Usage of any investigational drugs within 30 days prior to enrolment

         11. Alpha fetoprotein value &gt;100ng/mL at screening;

         12. Total bilirubin &gt; 1.5 x ULN with ratio of direct/indirect &gt; 1.

         13. ALT or AST level &gt; 10 x ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1220.40.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tulepo</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4303 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4301 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.1004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.1001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.1002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.1003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.1005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.3303A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.3305A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.3301A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.3306A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.3302A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.3304A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rennes Cedex 09</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4902 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4909 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4906 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4908 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4904 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4905 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1220.40.4003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Taiwan</country>
  </removed_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2009</study_first_submitted>
  <study_first_submitted_qc>September 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2009</study_first_posted>
  <results_first_submitted>July 3, 2015</results_first_submitted>
  <results_first_submitted_qc>August 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 7, 2015</results_first_posted>
  <disposition_first_submitted>March 27, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 27, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 24, 2014</disposition_first_posted>
  <last_update_submitted>August 7, 2015</last_update_submitted>
  <last_update_submitted_qc>August 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Faldaprevir 120mg (12 Weeks)</title>
          <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Faldaprevir 120mg (24 Weeks)</title>
          <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>reason other than listed above</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS): contained all randomised patients who were dispensed study medication and were documented to have taken at least one dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Faldaprevir 120 mg (12 Weeks)</title>
          <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Faldaprevir 120 mg (24 Weeks)</title>
          <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
            <count group_id="B2" value="79"/>
            <count group_id="B3" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.1" spread="9.4"/>
                    <measurement group_id="B2" value="44.9" spread="11.9"/>
                    <measurement group_id="B3" value="46.5" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Virological Response at Week 28 (W28VR)</title>
        <description>Virological response at Week 28: The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at Week 28.</description>
        <time_frame>28 weeks</time_frame>
        <population>Per Protocol Set (PPS): included all patients in the FAS without important protocol deviations.</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120 mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120 mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Virological Response at Week 28 (W28VR)</title>
          <description>Virological response at Week 28: The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at Week 28.</description>
          <population>Per Protocol Set (PPS): included all patients in the FAS without important protocol deviations.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.855</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on an Cochran−Mantel−Haenszel method adjusted by HCV genotype (1a and 1b only).</method_desc>
            <param_type>Adjusted percent difference</param_type>
            <param_value>-1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.3</ci_lower_limit>
            <ci_upper_limit>11.8</ci_upper_limit>
            <estimate_desc>p−value presented is 2−sided. The percent differences and p−values are based on a comparison to the Faldaprevir 120mg (12 Weeks).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rapid Virological Response at Week 4 (RVR)</title>
        <description>Rapid virological response at week 4 (RVR): The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at week 4.</description>
        <time_frame>4 weeks</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120 mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120 mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Rapid Virological Response at Week 4 (RVR)</title>
          <description>Rapid virological response at week 4 (RVR): The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at week 4.</description>
          <population>PPS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.229</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on an Cochran−Mantel−Haenszel method adjusted by HCV genotype (1a and 1b only).</method_desc>
            <param_type>Adjusted percent difference</param_type>
            <param_value>9.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>23.3</ci_upper_limit>
            <estimate_desc>p−value presented is 2−sided. The percent differences and p−values are based on a comparison to the Faldaprevir 120mg (12 Weeks).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virological Response at Week 24 (W24VR)</title>
        <description>virological response at week 24 (W24VR): The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at week 24.</description>
        <time_frame>24 weeks</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120 mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120 mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Virological Response at Week 24 (W24VR)</title>
          <description>virological response at week 24 (W24VR): The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at week 24.</description>
          <population>PPS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.417</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on an Cochran−Mantel−Haenszel method adjusted by HCV genotype (1a and 1b only).</method_desc>
            <param_type>Adjusted percent difference</param_type>
            <param_value>5.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>18.3</ci_upper_limit>
            <estimate_desc>p−value presented is 2−sided. The percent differences and p−values are based on a comparison to the Faldaprevir 120mg (12 Weeks).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Virological Response at Week 36 (W36VR)</title>
        <description>Virological response at week 36 (W36VR): the patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at week 36.</description>
        <time_frame>36 weeks</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120 mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120 mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Virological Response at Week 36 (W36VR)</title>
          <description>Virological response at week 36 (W36VR): the patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at week 36.</description>
          <population>PPS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.676</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on an Cochran−Mantel−Haenszel method adjusted by HCV genotype (1a and 1b only).</method_desc>
            <param_type>Adjusted percent difference</param_type>
            <param_value>2.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.6</ci_lower_limit>
            <ci_upper_limit>16.6</ci_upper_limit>
            <estimate_desc>p−value presented is 2−sided. The percent differences and p−values are based on a comparison to the Faldaprevir 120mg (12 Weeks).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End of Treatment Response (ETR)</title>
        <description>End of Treatment Response (ETR): The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at end of all therapy.</description>
        <time_frame>up to 48 weeks</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120 mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120 mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>End of Treatment Response (ETR)</title>
          <description>End of Treatment Response (ETR): The patients who reached plasma hepatitis C virus ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at end of all therapy.</description>
          <population>PPS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.588</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on an Cochran−Mantel−Haenszel method adjusted by HCV genotype (1a and 1b only).</method_desc>
            <param_type>Adjusted percent difference</param_type>
            <param_value>3.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.1</ci_lower_limit>
            <ci_upper_limit>14.6</ci_upper_limit>
            <estimate_desc>p−value presented is 2−sided. The percent differences and p−values are based on a comparison to the Faldaprevir 120mg (12 Weeks).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sustained Virological Response (SVR24) at 24 Weeks After Completion of All Therapy</title>
        <description>Sustained Virological Response (SVR24) at 24 weeks: The patients who reached plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at 24 weeks after completion of all Hepatitis C virus (HCV) therapy.</description>
        <time_frame>72 weeks</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120 mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120 mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Virological Response (SVR24) at 24 Weeks After Completion of All Therapy</title>
          <description>Sustained Virological Response (SVR24) at 24 weeks: The patients who reached plasma Hepatitis C virus Ribonucleic acid (HCV RNA) level below the lower limit of detection (BLD) at 24 weeks after completion of all Hepatitis C virus (HCV) therapy.</description>
          <population>PPS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.512</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Based on an Cochran−Mantel−Haenszel method adjusted by HCV genotype (1a and 1b only).</method_desc>
            <param_type>Adjusted percent difference</param_type>
            <param_value>4.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.0</ci_lower_limit>
            <ci_upper_limit>18.6</ci_upper_limit>
            <estimate_desc>p−value presented is 2−sided. The percent differences and p−values are based on a comparison to the Faldaprevir 120mg (12 Weeks).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Viral Load (HCV RNA) at All Visits During Treatment and Follow-up</title>
        <description>Viral load of Hepatitis C virus Ribonucleic acid (HCV RNA) at all visits during treatment (TRT) and follow-up, ie. change from baseline viral load at all visits.</description>
        <time_frame>From baseline to 72 weeks</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120 mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120 mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Viral Load (HCV RNA) at All Visits During Treatment and Follow-up</title>
          <description>Viral load of Hepatitis C virus Ribonucleic acid (HCV RNA) at all visits during treatment (TRT) and follow-up, ie. change from baseline viral load at all visits.</description>
          <population>PPS</population>
          <units>IU/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 2, change from baseline (N=76, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.724" spread="0.9059"/>
                    <measurement group_id="O2" value="-4.866" spread="0.8664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 4, change from baseline (N=76, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.993" spread="1.1168"/>
                    <measurement group_id="O2" value="-5.081" spread="1.1195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 8, change from baseline (N=75, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.128" spread="1.1159"/>
                    <measurement group_id="O2" value="-5.088" spread="1.3150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12, change from baseline (N=76, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.117" spread="1.1495"/>
                    <measurement group_id="O2" value="-5.107" spread="1.2852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16, change from baseline (N=18, N=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.363" spread="1.2341"/>
                    <measurement group_id="O2" value="-5.262" spread="0.5820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 20, change from baseline (N=52, N=57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.056" spread="1.0894"/>
                    <measurement group_id="O2" value="-5.366" spread="0.7319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24, change from baseline (N=12, N=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.176" spread="2.1635"/>
                    <measurement group_id="O2" value="-4.740" spread="1.6576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 28, change from baseline (N=4, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.723" spread="0.6795"/>
                    <measurement group_id="O2" value="-4.369" spread="2.2917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 36, change from baseline (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.624" spread="0.7059"/>
                    <measurement group_id="O2" value="-5.958" spread="0.1909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of TRT, change from baseline (N=80, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.910" spread="1.4690"/>
                    <measurement group_id="O2" value="-5.017" spread="1.4434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 wks after TRT, change from baseline (N=75, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.296" spread="2.2499"/>
                    <measurement group_id="O2" value="-4.367" spread="2.1849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 wks after TRT, change from baseline (N=75,N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.154" spread="2.3356"/>
                    <measurement group_id="O2" value="-4.353" spread="2.1588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 wks after TRT, change from baseline (N=73,N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.103" spread="2.3673"/>
                    <measurement group_id="O2" value="-4.250" spread="2.2439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Reach a Plasma HCV RNA Level BLD While on Treatment</title>
        <description>Time to reach a plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) level below the lower limit of detection (BLD) while on treatment</description>
        <time_frame>48 weeks</time_frame>
        <population>PPS</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120 mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120 mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach a Plasma HCV RNA Level BLD While on Treatment</title>
          <description>Time to reach a plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) level below the lower limit of detection (BLD) while on treatment</description>
          <population>PPS</population>
          <units>week</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O2" value="4.1" lower_limit="2" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1397</p_value>
            <p_value_desc>Compare 120 MG Faldaprevir 120mg (24 Weeks) over 120 MG Faldaprevir 120mg (12 Weeks) using log−rank test.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Test Abnormalities and Study Medication Tolerabilities</title>
        <description>Participants with possible clinically significant laboratory test abnormalities observed in functional groups: Haematology, Coagulation, Electrolytes, Enzymes, Substrates and Differentials, automatic.</description>
        <time_frame>48 weeks</time_frame>
        <population>Treated Set (TS): comprised all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment regardless of randomisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120 mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120 mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Test Abnormalities and Study Medication Tolerabilities</title>
          <description>Participants with possible clinically significant laboratory test abnormalities observed in functional groups: Haematology, Coagulation, Electrolytes, Enzymes, Substrates and Differentials, automatic.</description>
          <population>Treated Set (TS): comprised all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment regardless of randomisation.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Red blood cell count: low (N=81, N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>haematocrit: low (N=81, N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>haematocrit: high(N=81, N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>white blood cell count: low(N=81, N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>platelets: low(N=81, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>eosinophils: high (N=81, N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT-INR: high (N=81, N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sodium: low (N=81, N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bicarbonate: low (N=79, N=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>bicarbonate: high (N=79, N=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST/GOT, SGOT: high (N=75, N=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/GPT, SGPT: high (N=68, N=64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>alkaline phosphatase: high (N=80, N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT: high (N=74, N=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>creatine kinase: high (N=80, N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>lipase: high (N=79, N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>amylase: high (N=81, N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>glucose: low (N=80, N=79)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>cholesterol, total: high (N=80, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>triglyceride: high (N=74, N=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinically Relevant Abnormalities Vital Signs, and Physical Examination</title>
        <description>No number of participants with clinically relevant abnormalities in vital signs and physical examination.</description>
        <time_frame>48 weeks</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinically Relevant Abnormalities Vital Signs, and Physical Examination</title>
          <description>No number of participants with clinically relevant abnormalities in vital signs and physical examination.</description>
          <population>TS</population>
          <units>participants with abnormality</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (1)</title>
        <description>Change from baseline (CFB) in Red blood cells.</description>
        <time_frame>baseline and 48 weeks</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (1)</title>
          <description>Change from baseline (CFB) in Red blood cells.</description>
          <population>TS</population>
          <units>10^12 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Red blood cell (10^12cells/L) CFB,Day 1(N=77,N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.3"/>
                    <measurement group_id="O2" value="-0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell (10^12cells/L) CFB, wk2 (N=75,N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.5"/>
                    <measurement group_id="O2" value="-0.4" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell (10^12cells/L) CFB, wk4(N=74, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.5"/>
                    <measurement group_id="O2" value="-0.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell (10^12cells/L) CFB, wk8(N=75, N=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.5"/>
                    <measurement group_id="O2" value="-1.0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell (10^12cells/L) CFB, wk12(N=74,N=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.6"/>
                    <measurement group_id="O2" value="-1.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell (10^12cells/L) CFB, wk18(N=66,N=69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.6"/>
                    <measurement group_id="O2" value="-1.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell (10^12cells/L) CFB, wk24(N=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.7"/>
                    <measurement group_id="O2" value="-0.9" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell (10^12cells/L) CFB, wk28(N=4, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.4"/>
                    <measurement group_id="O2" value="-0.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell (10^12cells/L) CFB, wk36(N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.9"/>
                    <measurement group_id="O2" value="-1.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red blood cell (10^12cells/L) CFB, EoT(N=67, N=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.6"/>
                    <measurement group_id="O2" value="-1.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (2)</title>
        <description>Change from baseline (CFB) in haematocrit and Eosinophils.</description>
        <time_frame>baseline and 48 weeks</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (2)</title>
          <description>Change from baseline (CFB) in haematocrit and Eosinophils.</description>
          <population>TS</population>
          <units>% of laboratory test substance</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>haematocrit (%) CFB, Day1 (N=77, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="3.0"/>
                    <measurement group_id="O2" value="-1.3" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>haematocrit (%) CFB, wk2 (N=75, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="4.4"/>
                    <measurement group_id="O2" value="-4.7" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>haematocrit (%) CFB, wk4 (N=74, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="4.9"/>
                    <measurement group_id="O2" value="-7.9" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>haematocrit (%) CFB, wk8 (N=75, N=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="4.6"/>
                    <measurement group_id="O2" value="-7.1" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>haematocrit (%) CFB, wk12 (N=72, N=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="4.9"/>
                    <measurement group_id="O2" value="-7.8" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>haematocrit (%) CFB, wk18 (N=66, N=69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="5.4"/>
                    <measurement group_id="O2" value="-6.5" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>haematocrit (%) CFB, wk24 (N=11, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" spread="6.2"/>
                    <measurement group_id="O2" value="-2.7" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>haematocrit (%) CFB, wk28 (N=4, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="3.9"/>
                    <measurement group_id="O2" value="-1.2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>haematocrit (%) CFB, wk36 (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="8.0"/>
                    <measurement group_id="O2" value="-3.6" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>haematocrit (%) CFB, EoT (N=66, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="4.7"/>
                    <measurement group_id="O2" value="-6.0" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils(%), CFB, day1 (N=77, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="1"/>
                    <measurement group_id="O2" value="0" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils(%), CFB, wk2 (N=75, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="2"/>
                    <measurement group_id="O2" value="0" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils(%), CFB, wk4 (N=73, N=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1"/>
                    <measurement group_id="O2" value="0" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils(%), CFB, wk8 (N=74, N=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="2"/>
                    <measurement group_id="O2" value="0" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils(%), CFB, wk12 (N=72, N=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="2"/>
                    <measurement group_id="O2" value="0" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils(%), CFB, wk18 (N=62, N=65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="3"/>
                    <measurement group_id="O2" value="0" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils(%), CFB, wk24 (N=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1"/>
                    <measurement group_id="O2" value="-1" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils(%), CFB, wk28 (N=4, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1"/>
                    <measurement group_id="O2" value="-2" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils(%), CFB, wk36 (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1"/>
                    <measurement group_id="O2" value="-1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils(%), CFB, EoT (N=66, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="2"/>
                    <measurement group_id="O2" value="1" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (3)</title>
        <description>Change from baseline (CFB) in Platelets and white blood cells.</description>
        <time_frame>baseline and 48 weeks</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (3)</title>
          <description>Change from baseline (CFB) in Platelets and white blood cells.</description>
          <population>TS</population>
          <units>10^9 cells/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Platelets CFB, Day 1 (N=77, N=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="35"/>
                    <measurement group_id="O2" value="2" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets CFB, wk2 (N=74, N=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35" spread="40"/>
                    <measurement group_id="O2" value="-35" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets CFB, wk4 (N=73, N=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35" spread="41"/>
                    <measurement group_id="O2" value="-39" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets CFB, wk8 (N=73, N=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55" spread="37"/>
                    <measurement group_id="O2" value="-48" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets CFB, wk12 (N=72, N=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61" spread="38"/>
                    <measurement group_id="O2" value="-50" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets CFB, wk18 (N=66, N=68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55" spread="46"/>
                    <measurement group_id="O2" value="-51" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets CFB, wk24 (N=12, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46" spread="37"/>
                    <measurement group_id="O2" value="-50" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets CFB, wk28 (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22" spread="77"/>
                    <measurement group_id="O2" value="-83" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets CFB, wk36 (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47" spread="31"/>
                    <measurement group_id="O2" value="-85" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets CFB, EoT (N=67, N=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59" spread="46"/>
                    <measurement group_id="O2" value="-50" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>white blood cell CFB, day1 (N=77, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.1"/>
                    <measurement group_id="O2" value="0.3" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>white blood cell CFB, wk2 (N=75, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="1.5"/>
                    <measurement group_id="O2" value="-1.8" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>white blood cell CFB, wk4 (N=74, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="1.5"/>
                    <measurement group_id="O2" value="-2.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>white blood cell CFB, wk8 (N=75, N=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="1.5"/>
                    <measurement group_id="O2" value="-2.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>white blood cell CFB, wk12 (N=74, N=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="1.5"/>
                    <measurement group_id="O2" value="-2.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>white blood cell CFB, wk18 (N=66, N=69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="1.4"/>
                    <measurement group_id="O2" value="-3.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>white blood cell CFB, wk24 (N=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="1.3"/>
                    <measurement group_id="O2" value="-2.0" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>white blood cell CFB, wk28 (N=4, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="1.0"/>
                    <measurement group_id="O2" value="-1.9" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>white blood cell CFB, wk36 (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="0.9"/>
                    <measurement group_id="O2" value="-3.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>white blood cell CFB, EoT (N=67, N=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="1.5"/>
                    <measurement group_id="O2" value="-3.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (4)</title>
        <description>Change from baseline (CFB) in Sodium, Bicarbonate, Cholesterol total, Triglyceride, and Glucose.</description>
        <time_frame>baseline and 48 weeks</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (4)</title>
          <description>Change from baseline (CFB) in Sodium, Bicarbonate, Cholesterol total, Triglyceride, and Glucose.</description>
          <population>TS</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium (mmol/L) CFB, Day 1(N=77, N=74)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="2"/>
                    <measurement group_id="O2" value="1" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (mmol/L) CFB, wk2 (N=76, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="2"/>
                    <measurement group_id="O2" value="0" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (mmol/L) CFB, wk4 (N=76, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="2"/>
                    <measurement group_id="O2" value="0" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (mmol/L) CFB, wk8 (N=73, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="3"/>
                    <measurement group_id="O2" value="1" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (mmol/L) CFB, wk12 (N=75, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="2"/>
                    <measurement group_id="O2" value="1" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (mmol/L) CFB, wk18 (N=68, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="2"/>
                    <measurement group_id="O2" value="0" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (mmol/L) CFB, wk24 (N=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="2"/>
                    <measurement group_id="O2" value="0" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (mmol/L) CFB, wk28 (N=5, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="2"/>
                    <measurement group_id="O2" value="-1" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (mmol/L) CFB, wk36 (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="2"/>
                    <measurement group_id="O2" value="-1" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (mmol/L) CFB, EoT (N=67, N=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="2"/>
                    <measurement group_id="O2" value="0" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (mmol/L), CFB, day1 (N=76, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.4"/>
                    <measurement group_id="O2" value="0.2" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (mmol/L), CFB, wk2 (N=75, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.4"/>
                    <measurement group_id="O2" value="0.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (mmol/L), CFB, wk4 (N=74, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.3"/>
                    <measurement group_id="O2" value="-0.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (mmol/L), CFB, wk8 (N=74, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.3"/>
                    <measurement group_id="O2" value="0.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (mmol/L), CFB, wk12 (N=74, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.2"/>
                    <measurement group_id="O2" value="-0.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (mmol/L), CFB, wk18 (N=66, N=69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.6"/>
                    <measurement group_id="O2" value="-0.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (mmol/L), CFB, wk24 (N=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.4"/>
                    <measurement group_id="O2" value="-0.5" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (mmol/L), CFB, wk28 (N=4, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="2.1"/>
                    <measurement group_id="O2" value="-0.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (mmol/L), CFB, wk36 (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="2.3"/>
                    <measurement group_id="O2" value="-1.0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate (mmol/L), CFB, EoT (N=64, N=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.6"/>
                    <measurement group_id="O2" value="-0.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol tot. (mmol/L), CFB, day1 (n=77, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.47"/>
                    <measurement group_id="O2" value="-0.05" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol tot. (mmol/L), CFB, wk2 (n=76, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.57"/>
                    <measurement group_id="O2" value="-0.54" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol tot. (mmol/L), CFB, wk4 (n=76, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.55"/>
                    <measurement group_id="O2" value="-0.67" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol tot. (mmol/L), CFB, wk8 (n=75, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.58" spread="0.59"/>
                    <measurement group_id="O2" value="-0.60" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol tot. (mmol/L), CFB, wk12 (n=75, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="0.62"/>
                    <measurement group_id="O2" value="-0.74" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol tot. (mmol/L), CFB, wk18 (n=68, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.64"/>
                    <measurement group_id="O2" value="-0.80" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol tot. (mmol/L), CFB, wk24 (n=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.46"/>
                    <measurement group_id="O2" value="-0.37" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol tot. (mmol/L), CFB, wk28 (n=5, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.53"/>
                    <measurement group_id="O2" value="-0.09" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol tot. (mmol/L), CFB, wk36 (n=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" spread="0.14"/>
                    <measurement group_id="O2" value="-0.23" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol tot. (mmol/L), CFB, EoT (n=67, N=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.70"/>
                    <measurement group_id="O2" value="-0.74" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride (mmol/L), CFB, day1 (N=77, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.5"/>
                    <measurement group_id="O2" value="-0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride (mmol/L), CFB, wk2 (N=76, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5"/>
                    <measurement group_id="O2" value="0.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride (mmol/L), CFB, wk4 (N=76, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5"/>
                    <measurement group_id="O2" value="0.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride (mmol/L), CFB, wk8 (N=75, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5"/>
                    <measurement group_id="O2" value="0.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride (mmol/L), CFB, wk12 (N=75, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.6"/>
                    <measurement group_id="O2" value="0.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride (mmol/L), CFB, wk18 (N=68, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.5"/>
                    <measurement group_id="O2" value="0.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride (mmol/L), CFB, wk24 (N=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.7"/>
                    <measurement group_id="O2" value="0.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride (mmol/L), CFB, wk28 (N=5, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.3"/>
                    <measurement group_id="O2" value="0.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride (mmol/L), CFB, wk36 (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.7"/>
                    <measurement group_id="O2" value="0.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride (mmol/L), CFB, EoT (N=67, N=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.6"/>
                    <measurement group_id="O2" value="0.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (mmol/L), CFB, day1 (N=76, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.3"/>
                    <measurement group_id="O2" value="0.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (mmol/L), CFB, wk2 (N=75, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.3"/>
                    <measurement group_id="O2" value="0.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (mmol/L), CFB, wk4 (N=74, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.3"/>
                    <measurement group_id="O2" value="0.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (mmol/L), CFB, wk8 (N=74, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.3"/>
                    <measurement group_id="O2" value="0.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (mmol/L), CFB, wk12 (N=73, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.1"/>
                    <measurement group_id="O2" value="-0.1" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (mmol/L), CFB, wk18 (N=67, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.2"/>
                    <measurement group_id="O2" value="-0.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (mmol/L), CFB, wk24 (N=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.3"/>
                    <measurement group_id="O2" value="-0.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (mmol/L), CFB, wk28 (N=5, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.1"/>
                    <measurement group_id="O2" value="0.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (mmol/L), CFB, wk36 (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.7"/>
                    <measurement group_id="O2" value="-0.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (mmol/L), CFB, EoT (N=66, N=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.2"/>
                    <measurement group_id="O2" value="-0.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (5)</title>
        <description>Change from baseline (CFB) in AST/GOT, ALT/GPT, Alka. phosphatase, GGT, Creatine kinase, Lipase, and Amylase.</description>
        <time_frame>baseline and 48 weeks</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (5)</title>
          <description>Change from baseline (CFB) in AST/GOT, ALT/GPT, Alka. phosphatase, GGT, Creatine kinase, Lipase, and Amylase.</description>
          <population>TS</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AST/GOT (U/L), CFB, Day 1(N=74, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="28"/>
                    <measurement group_id="O2" value="-5" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST/GOT (U/L), CFB, wk2 (N=75, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24" spread="30"/>
                    <measurement group_id="O2" value="-29" spread="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST/GOT (U/L), CFB, wk4 (N=74, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25" spread="31"/>
                    <measurement group_id="O2" value="-29" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST/GOT (U/L), CFB, wk8 (N=74, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22" spread="36"/>
                    <measurement group_id="O2" value="-27" spread="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST/GOT (U/L), CFB, wk12 (N=74, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24" spread="29"/>
                    <measurement group_id="O2" value="-27" spread="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST/GOT (U/L), CFB, wk18 (N=67, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25" spread="33"/>
                    <measurement group_id="O2" value="-30" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST/GOT (U/L), CFB, wk24 (N=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23" spread="60"/>
                    <measurement group_id="O2" value="-10" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST/GOT (U/L), CFB, wk28 (N=5, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20" spread="27"/>
                    <measurement group_id="O2" value="-16" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST/GOT (U/L), CFB, wk36 (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21" spread="40"/>
                    <measurement group_id="O2" value="11" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST/GOT (U/L), CFB, EoT (N=66, N=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25" spread="41"/>
                    <measurement group_id="O2" value="-27" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/GPT (U/L), CFB, day1 (N=76, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="24"/>
                    <measurement group_id="O2" value="-2" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/GPT (U/L), CFB, wk2 (N=75, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37" spread="36"/>
                    <measurement group_id="O2" value="-34" spread="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/GPT (U/L), CFB, wk4 (N=74, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37" spread="40"/>
                    <measurement group_id="O2" value="-34" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/GPT (U/L), CFB, wk8 (N=74, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-36" spread="43"/>
                    <measurement group_id="O2" value="-35" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/GPT (U/L), CFB, wk12 (N=74, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37" spread="36"/>
                    <measurement group_id="O2" value="-36" spread="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/GPT (U/L), CFB, wk18 (N=67, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41" spread="40"/>
                    <measurement group_id="O2" value="-42" spread="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/GPT (U/L), CFB, wk24 (N=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40" spread="50"/>
                    <measurement group_id="O2" value="-24" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/GPT (U/L), CFB, wk28 (N=5, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45" spread="38"/>
                    <measurement group_id="O2" value="-22" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/GPT (U/L), CFB, wk36 (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-47" spread="46"/>
                    <measurement group_id="O2" value="-6" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT/GPT (U/L), CFB, EoT (N=66, N=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42" spread="42"/>
                    <measurement group_id="O2" value="-42" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alka. phosphatase (U/L), CFB, day1 (n=77, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="11"/>
                    <measurement group_id="O2" value="1" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alka. phosphatase (U/L), CFB, wk2 (n=76, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="10"/>
                    <measurement group_id="O2" value="7" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alka. phosphatase (U/L), CFB, wk4 (n=76, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="13"/>
                    <measurement group_id="O2" value="10" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alka. phosphatase (U/L), CFB, wk8 (n=75, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="13"/>
                    <measurement group_id="O2" value="9" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alka. phosphatase (U/L), CFB, wk12 (n=75, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="14"/>
                    <measurement group_id="O2" value="6" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alka. phosphatase (U/L), CFB, wk18 (n=68, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="20"/>
                    <measurement group_id="O2" value="5" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alka. phosphatase (U/L), CFB, wk24 (n=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14" spread="24"/>
                    <measurement group_id="O2" value="13" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alka. phosphatase (U/L), CFB, wk28 (n=5, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="14"/>
                    <measurement group_id="O2" value="15" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alka. phosphatase (U/L), CFB, wk36 (n=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" spread="16"/>
                    <measurement group_id="O2" value="18" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alka. phosphatase (U/L), CFB, EoT (n=67, N=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="22"/>
                    <measurement group_id="O2" value="5" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT (U/L), CFB, day1 (N=77, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" spread="39"/>
                    <measurement group_id="O2" value="-5" spread="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT (U/L), CFB, wk2 (N=76, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-34" spread="71"/>
                    <measurement group_id="O2" value="-38" spread="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT (U/L), CFB, wk4 (N=76, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59" spread="86"/>
                    <measurement group_id="O2" value="-60" spread="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT (U/L), CFB, wk8 (N=75, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-76" spread="96"/>
                    <measurement group_id="O2" value="-70" spread="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT (U/L), CFB, wk12 (N=75, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-71" spread="103"/>
                    <measurement group_id="O2" value="-69" spread="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT (U/L), CFB, wk18 (N=68, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-62" spread="105"/>
                    <measurement group_id="O2" value="-64" spread="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT (U/L), CFB, wk24 (N=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-118" spread="200"/>
                    <measurement group_id="O2" value="-131" spread="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT (U/L), CFB, wk28 (N=5, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52" spread="126"/>
                    <measurement group_id="O2" value="-113" spread="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT (U/L), CFB, wk36 (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23" spread="132"/>
                    <measurement group_id="O2" value="-14" spread="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT (U/L), CFB, EoT (N=67, N=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39" spread="106"/>
                    <measurement group_id="O2" value="-59" spread="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase (U/L), CFB, day1 (N=76, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="140"/>
                    <measurement group_id="O2" value="30" spread="308"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase (U/L), CFB, wk2 (N=75, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59" spread="158"/>
                    <measurement group_id="O2" value="-41" spread="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase (U/L), CFB, wk4 (N=74, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69" spread="173"/>
                    <measurement group_id="O2" value="-62" spread="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase (U/L), CFB, wk8 (N=74, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-92" spread="176"/>
                    <measurement group_id="O2" value="-75" spread="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase (U/L), CFB, wk12 (N=74, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-98" spread="186"/>
                    <measurement group_id="O2" value="-84" spread="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase (U/L), CFB, wk18 (N=67, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-93" spread="202"/>
                    <measurement group_id="O2" value="-60" spread="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase (U/L), CFB, wk24 (N=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-69" spread="78"/>
                    <measurement group_id="O2" value="-42" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase (U/L), CFB, wk28 (N=5, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48" spread="75"/>
                    <measurement group_id="O2" value="-32" spread="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase (U/L), CFB, wk36 (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-68" spread="83"/>
                    <measurement group_id="O2" value="-37" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine kinase (U/L), CFB, EoT (N=66, N=71)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-89" spread="187"/>
                    <measurement group_id="O2" value="-21" spread="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase (U/L). CFB, day1 (N=77, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="52"/>
                    <measurement group_id="O2" value="26" spread="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase (U/L). CFB, wk2 (N=76, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="65"/>
                    <measurement group_id="O2" value="9" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase (U/L). CFB, wk4 (N=76, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="52"/>
                    <measurement group_id="O2" value="6" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase (U/L). CFB, wk8 (N=75, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11" spread="69"/>
                    <measurement group_id="O2" value="2" spread="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase (U/L). CFB, wk12 (N=75, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12" spread="70"/>
                    <measurement group_id="O2" value="4" spread="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase (U/L). CFB, wk18 (N=68, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13" spread="64"/>
                    <measurement group_id="O2" value="-4" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase (U/L). CFB, wk24 (N=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="31"/>
                    <measurement group_id="O2" value="-17" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase (U/L). CFB, wk28 (N=5, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="13"/>
                    <measurement group_id="O2" value="0" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase (U/L). CFB, wk36 (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" spread="12"/>
                    <measurement group_id="O2" value="-15" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase (U/L). CFB, EoT (N=67, N=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" spread="82"/>
                    <measurement group_id="O2" value="-5" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (U/L), CFB, day1 (N=77, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="26"/>
                    <measurement group_id="O2" value="7" spread="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (U/L), CFB, wk2 (N=76, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="41"/>
                    <measurement group_id="O2" value="3" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (U/L), CFB, wk4 (N=76, N=77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="30"/>
                    <measurement group_id="O2" value="5" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (U/L), CFB, wk8 (N=75, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" spread="33"/>
                    <measurement group_id="O2" value="-2" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (U/L), CFB, wk12 (N=75, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" spread="33"/>
                    <measurement group_id="O2" value="-4" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (U/L), CFB, wk18 (N=68, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7" spread="34"/>
                    <measurement group_id="O2" value="-7" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (U/L), CFB, wk24 (N=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14" spread="35"/>
                    <measurement group_id="O2" value="-16" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (U/L), CFB, wk28 (N=5, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21" spread="34"/>
                    <measurement group_id="O2" value="-8" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (U/L), CFB, wk36 (N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35" spread="24"/>
                    <measurement group_id="O2" value="-19" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase (U/L), CFB, EoT (N=67, N=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="37"/>
                    <measurement group_id="O2" value="-4" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (6)</title>
        <description>Change from baseline (CFB) in PT-INR (ratio).</description>
        <time_frame>baseline and 48 weeks</time_frame>
        <population>TS</population>
        <group_list>
          <group group_id="O1">
            <title>Faldaprevir 120mg (12 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks. Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Faldaprevir 120mg (24 Weeks)</title>
            <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV). Patients who did not show an extended early virological response (eRVR) continued treatment with PegIFN/RBV alone for a total of 24 to 48 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (6)</title>
          <description>Change from baseline (CFB) in PT-INR (ratio).</description>
          <population>TS</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PT-INR (ratio), CFB, Day 1(N=77, N=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.2"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT-INR (ratio), CFB, wk2 (N=76, N=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT-INR (ratio), CFB, wk4(N=74, N=76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT-INR (ratio), CFB, wk8(N=73, N=75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT-INR (ratio), CFB, wk12(N=74, N=72)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT-INR (ratio), CFB, wk18(N=69, N=70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT-INR (ratio), CFB, wk24(N=12, N=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT-INR (ratio), CFB, wk28(N=5, N=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT-INR (ratio), CFB, wk36(N=4, N=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="-0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PT-INR (ratio), CFB, EoT(N=68, N=73)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>up to 24 weeks + 30 days washout.</time_frame>
      <desc>One patient, randomised to the 12 week treatment, received PegIFN/RBV during the lead-in phase but never started treatment with Faldaprevir and therefore is not included in the adverse event summary.</desc>
      <group_list>
        <group group_id="E1">
          <title>Faldaprevir 120 mg (12 Weeks)</title>
          <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 12 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV), followed by PegIFN/RBV for additional 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Faldaprevir 120 mg (24 Weeks)</title>
          <description>Patients received Faldaprevir (BI201335) 120 mg soft gelatine capsule once daily combined with PegIFN/RBV (Pegylated interferon alpha-2a solution for injection/Ribavirin tablet) for 24 weeks, with a 3 days lead-in phase of PegIFN/RBV (i.e. initiation of Faldaprevir (BI201335) 3 days after first administration of PegIFN/RBV).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

